This report describes a unique case of isolated intracranial mucormycosis of a slowly progressive nature in a healthy immunocompetent child. A 4-year-old girl with a clear medical and surgical history presented with complaints of right side facial asymmetry and unsteady gait for a period of 10 months. Clinical and radiographic investigations revealed right-sided lower motor neuron facial palsy caused by an infiltrative lesion on the right cerebellopontine angle. Initial surgical debulking was performed, a biopsy was sent for histopathological examination, and a course of prophylactic antibiotic and antifungal drugs was prescribed. The pathological report confirmed the mucormycosis fungal infection, and intravenous amphotericin B was administered for 3 weeks. One month after admission, the patient left the hospital with complete recovery. Follow-ups after 4, 8 and 12 weeks revealed no sensory or motor neurological deficits. In conclusion, this is a unique case of mucormycosis with regard to the nature and location of the infection, along with the host being a healthy child. Initial surgical exploration is a very critical step in the early diagnosis and treatment of such rare conditions.

Keywords:
Amphotericin B, Fungal infection, Immunocompetence, Indolence, Mucormycosis
1.
Kwon-Chung KJ: Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives. Clin Infect Dis 2012;54:S8-S15.
2.
Alrefai AH, Berger JR, Saadeh RS: Against all odds: surviving rhino-orbital-cerebral mucormycosis: a case report. J Neurovirol 2012;18:144-147.
3.
Han SR, Choi CY, Joo M, Whang CJ: Isolated cerebral mucormycosis. J Korean Neurosurg Soc 2007;42:400-402.
4.
Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP: Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012;54:S23-S34.
5.
Air EL, Vagal AA, Kendler A, McPherson CM: Isolated cerebellar mucormycosis, slowly progressive over 1 year in an immunocompetent patient. Surg Neurol Int 2010;1:81.
6.
Malik AN, Bi WL, McCray B, Abedalthagafi M, Vaitkevicius H, Dunn IF: Isolated cerebral mucormycosis of the basal ganglia. Clin Neurol Neurosurg 2014;124:102-105.
7.
Rumboldt Z, Castillo M: Indolent intracranial mucormycosis: case report. Am J Neuroradiol 2002;23:932-934.
8.
Verma A, Brozman B, Petito CK: Isolated cerebral mucormycosis: report of a case and review of the literature. J Neurol Sci 2006;240:65-69.
9.
Uy EM, Rustagi T, Khera S: Cerebral mucormycosis in a diabetic man. Conn Med 2011;75:273-279.
10.
Tsung LL, Zhu XL, Chu WC, Sun DT, Cheung KL, Leung TF: Intraventricular amphotericin for absidiomycosis in an immunocompetent child. Hong Kong Med J 2010;16:137-140.
11.
Jang TY: Pathogenesis of nasal polyps. J Rhinol 1999;6:5-11.
12.
Telmesani LM: Prevalence of allergic fungal sinusitis among patients with nasal polyps. Ann Saudi Med 2009;29:212-214.
13.
Braun H, Buzina W, Freudenschuss K, Beham A, Stammberger H: ‘Eosinophilic fungal rhinosinusitis': a common disorder in Europe? Laryngoscope 2003;113:264-269.
14.
Corradini C, Del Ninno M, Buonomo A, Nucera E, Paludetti G, Alonzi C, Sabato V, Schiavino D, Patriarca G: Amphotericin B and lysine acetylsalicylate in the combined treatment of nasal polyposis associated with mycotic infection. J Investig Allergol Clin Immunol 2006;16:188-193.
15.
Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J Jr, Ibrahim AS: Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis 2009;48:1743-1751.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.